Recombinant apolipoprotein A-I Milano rapidly reverses aortic valve stenosis and decreases leaflet inflammation in an experimental rabbit model

Walter S. Speidl, Giovanni Cimmino, Borja Ibanez, Sammy Elmariah, Randolph Hutter, Mario J. Garcia, Valentin Fuster, Martin E. Goldman, Juan J. Badimon

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Aims Aortic stenosis (AS) is associated with significant morbidity and mortality. Recombinant apolipoprotein A-I Milano (rApoA-IM) induces atherosclerotic plaque regression. The Aims of this study were to determine the effects of rApoA-IM on experimental aortic valve degeneration and its mechanisms of action. Methods and results New Zealand White rabbits (n = 20) were fed an atherogenic diet for 9 months and then randomized to either placebo or rApoA-IM. Echocardiography was used to assess the effect of the treatments on AS. Porcine aortic valve myofibroblasts (PAVMF) treated with oxidized low-density lipoprotein served to define the effects of rApoA-IM on the expression of monocyte chemoattractant protein-1 (MCP-1), nuclear factor (NF)-B, and alkaline phosphatase (AP). Recombinant apolipoprotein A-I Milano increased aortic valve area (AVA) by 32 (0.25 ± 0.05 to 0.34 ± 0.07 cm2, P < 0.01); whereas AVA remained unchanged in the placebo group (0.24 ± 0.05 to 0.26 ± 0.04 cm2, P = 0.58). Histopathological examination of aortic valves in the rApoA-IM animals showed significantly less leaflet thickening, inflammation, and calcification vs. the placebo group. In vitro, rApoA-IM significantly inhibited MCP-1, AP, and NF-B and decreased intracellular cholesterol content in PAVMF. Conclusion Recombinant apolipoprotein A-I Milano treatment reverses AS in this experimental rabbit model. The beneficial effects seem to be mediated by enhanced cholesterol removal and by reduced inflammation and calcification.

Original languageEnglish (US)
Pages (from-to)2049-2057
Number of pages9
JournalEuropean Heart Journal
Volume31
Issue number16
DOIs
StatePublished - Aug 2010
Externally publishedYes

Fingerprint

Aortic Valve Stenosis
Theoretical Models
Aortic Valve
Rabbits
Inflammation
Myofibroblasts
Chemokine CCL2
Placebos
Alkaline Phosphatase
Swine
Cholesterol
Atherogenic Diet
apolipoprotein A-I Milano
Atherosclerotic Plaques
Echocardiography
Morbidity
Mortality
Therapeutics

Keywords

  • Aortic valve stenosis
  • Apolipoprotein A-I Milano
  • Calcification
  • Inflammation
  • Myofibroblast

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Recombinant apolipoprotein A-I Milano rapidly reverses aortic valve stenosis and decreases leaflet inflammation in an experimental rabbit model. / Speidl, Walter S.; Cimmino, Giovanni; Ibanez, Borja; Elmariah, Sammy; Hutter, Randolph; Garcia, Mario J.; Fuster, Valentin; Goldman, Martin E.; Badimon, Juan J.

In: European Heart Journal, Vol. 31, No. 16, 08.2010, p. 2049-2057.

Research output: Contribution to journalArticle

Speidl, Walter S. ; Cimmino, Giovanni ; Ibanez, Borja ; Elmariah, Sammy ; Hutter, Randolph ; Garcia, Mario J. ; Fuster, Valentin ; Goldman, Martin E. ; Badimon, Juan J. / Recombinant apolipoprotein A-I Milano rapidly reverses aortic valve stenosis and decreases leaflet inflammation in an experimental rabbit model. In: European Heart Journal. 2010 ; Vol. 31, No. 16. pp. 2049-2057.
@article{d61de824d45b430eb8ea764a6bd56fcf,
title = "Recombinant apolipoprotein A-I Milano rapidly reverses aortic valve stenosis and decreases leaflet inflammation in an experimental rabbit model",
abstract = "Aims Aortic stenosis (AS) is associated with significant morbidity and mortality. Recombinant apolipoprotein A-I Milano (rApoA-IM) induces atherosclerotic plaque regression. The Aims of this study were to determine the effects of rApoA-IM on experimental aortic valve degeneration and its mechanisms of action. Methods and results New Zealand White rabbits (n = 20) were fed an atherogenic diet for 9 months and then randomized to either placebo or rApoA-IM. Echocardiography was used to assess the effect of the treatments on AS. Porcine aortic valve myofibroblasts (PAVMF) treated with oxidized low-density lipoprotein served to define the effects of rApoA-IM on the expression of monocyte chemoattractant protein-1 (MCP-1), nuclear factor (NF)-B, and alkaline phosphatase (AP). Recombinant apolipoprotein A-I Milano increased aortic valve area (AVA) by 32 (0.25 ± 0.05 to 0.34 ± 0.07 cm2, P < 0.01); whereas AVA remained unchanged in the placebo group (0.24 ± 0.05 to 0.26 ± 0.04 cm2, P = 0.58). Histopathological examination of aortic valves in the rApoA-IM animals showed significantly less leaflet thickening, inflammation, and calcification vs. the placebo group. In vitro, rApoA-IM significantly inhibited MCP-1, AP, and NF-B and decreased intracellular cholesterol content in PAVMF. Conclusion Recombinant apolipoprotein A-I Milano treatment reverses AS in this experimental rabbit model. The beneficial effects seem to be mediated by enhanced cholesterol removal and by reduced inflammation and calcification.",
keywords = "Aortic valve stenosis, Apolipoprotein A-I Milano, Calcification, Inflammation, Myofibroblast",
author = "Speidl, {Walter S.} and Giovanni Cimmino and Borja Ibanez and Sammy Elmariah and Randolph Hutter and Garcia, {Mario J.} and Valentin Fuster and Goldman, {Martin E.} and Badimon, {Juan J.}",
year = "2010",
month = "8",
doi = "10.1093/eurheartj/ehq064",
language = "English (US)",
volume = "31",
pages = "2049--2057",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "16",

}

TY - JOUR

T1 - Recombinant apolipoprotein A-I Milano rapidly reverses aortic valve stenosis and decreases leaflet inflammation in an experimental rabbit model

AU - Speidl, Walter S.

AU - Cimmino, Giovanni

AU - Ibanez, Borja

AU - Elmariah, Sammy

AU - Hutter, Randolph

AU - Garcia, Mario J.

AU - Fuster, Valentin

AU - Goldman, Martin E.

AU - Badimon, Juan J.

PY - 2010/8

Y1 - 2010/8

N2 - Aims Aortic stenosis (AS) is associated with significant morbidity and mortality. Recombinant apolipoprotein A-I Milano (rApoA-IM) induces atherosclerotic plaque regression. The Aims of this study were to determine the effects of rApoA-IM on experimental aortic valve degeneration and its mechanisms of action. Methods and results New Zealand White rabbits (n = 20) were fed an atherogenic diet for 9 months and then randomized to either placebo or rApoA-IM. Echocardiography was used to assess the effect of the treatments on AS. Porcine aortic valve myofibroblasts (PAVMF) treated with oxidized low-density lipoprotein served to define the effects of rApoA-IM on the expression of monocyte chemoattractant protein-1 (MCP-1), nuclear factor (NF)-B, and alkaline phosphatase (AP). Recombinant apolipoprotein A-I Milano increased aortic valve area (AVA) by 32 (0.25 ± 0.05 to 0.34 ± 0.07 cm2, P < 0.01); whereas AVA remained unchanged in the placebo group (0.24 ± 0.05 to 0.26 ± 0.04 cm2, P = 0.58). Histopathological examination of aortic valves in the rApoA-IM animals showed significantly less leaflet thickening, inflammation, and calcification vs. the placebo group. In vitro, rApoA-IM significantly inhibited MCP-1, AP, and NF-B and decreased intracellular cholesterol content in PAVMF. Conclusion Recombinant apolipoprotein A-I Milano treatment reverses AS in this experimental rabbit model. The beneficial effects seem to be mediated by enhanced cholesterol removal and by reduced inflammation and calcification.

AB - Aims Aortic stenosis (AS) is associated with significant morbidity and mortality. Recombinant apolipoprotein A-I Milano (rApoA-IM) induces atherosclerotic plaque regression. The Aims of this study were to determine the effects of rApoA-IM on experimental aortic valve degeneration and its mechanisms of action. Methods and results New Zealand White rabbits (n = 20) were fed an atherogenic diet for 9 months and then randomized to either placebo or rApoA-IM. Echocardiography was used to assess the effect of the treatments on AS. Porcine aortic valve myofibroblasts (PAVMF) treated with oxidized low-density lipoprotein served to define the effects of rApoA-IM on the expression of monocyte chemoattractant protein-1 (MCP-1), nuclear factor (NF)-B, and alkaline phosphatase (AP). Recombinant apolipoprotein A-I Milano increased aortic valve area (AVA) by 32 (0.25 ± 0.05 to 0.34 ± 0.07 cm2, P < 0.01); whereas AVA remained unchanged in the placebo group (0.24 ± 0.05 to 0.26 ± 0.04 cm2, P = 0.58). Histopathological examination of aortic valves in the rApoA-IM animals showed significantly less leaflet thickening, inflammation, and calcification vs. the placebo group. In vitro, rApoA-IM significantly inhibited MCP-1, AP, and NF-B and decreased intracellular cholesterol content in PAVMF. Conclusion Recombinant apolipoprotein A-I Milano treatment reverses AS in this experimental rabbit model. The beneficial effects seem to be mediated by enhanced cholesterol removal and by reduced inflammation and calcification.

KW - Aortic valve stenosis

KW - Apolipoprotein A-I Milano

KW - Calcification

KW - Inflammation

KW - Myofibroblast

UR - http://www.scopus.com/inward/record.url?scp=77955960185&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955960185&partnerID=8YFLogxK

U2 - 10.1093/eurheartj/ehq064

DO - 10.1093/eurheartj/ehq064

M3 - Article

C2 - 20304838

AN - SCOPUS:77955960185

VL - 31

SP - 2049

EP - 2057

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

IS - 16

ER -